Orsini Specialty Pharmacy, an Illinois-based company involved in rare disease pharmacy solutions, announced on Monday that it has been chosen by Massachusetts-based KalVista Pharmaceuticals as a specialty pharmacy partner for EKTERLY (sebetralstat), an FDA-approved oral therapy for the treatment of acute attacks of hereditary angioedema (HAE) in adult and paediatric patients aged 12 years and older.

HAE is a life-threatening inherited genetic disorder that can affect the autoimmune system, causing recurrent episodes of severe swelling, most commonly in the limbs, face, intestines and airway. The condition is a result of low levels or improper functioning of a protein called C1 inhibitor. While minor trauma or stress could trigger an attack, swelling often occurs without a known trigger.

EKTERLY is administered at the onset of an HAE attack to quickly relieve symptoms and reduce the severity and duration of the episode. It is the tenth HAE therapy to join Orsini's portfolio.